At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZYME ZYMEWORKS INC (US)
Post-Mkt 03-13 18:15:30 EDT
22.88
-0.35
-1.51%
盘后22.88
+0.000.00%
16:10 EDT
High23.89Low22.43Vol787.02K
Open23.42D1 Closing23.23Amplitude6.29%
Mkt Cap1.69BTradable Cap876.29MTotal Shares73.75M
T/O18.01MT/O Rate2.05%Tradable Shares38.30M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts’ Top Healthcare Picks: GeneDx Holdings (WGS), Zymeworks (ZYME)
TIPRANKS  ·  03-12 20:30
Analysts’ Top Healthcare Picks: GeneDx Holdings (WGS), Zymeworks (ZYME)
Zymeworks Is Maintained at Outperform by Evercore ISI Group
Dow Jones  ·  03-10
Zymeworks Is Maintained at Outperform by Evercore ISI Group
Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook
TIPRANKS  ·  03-09
Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook
Zymeworks Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  03-06
Zymeworks Is Maintained at Buy by HC Wainwright & Co.
Stock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases
Stock Track  ·  03-04
Stock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases
Zymeworks Is Maintained at Outperform by Leerink Partners
Dow Jones  ·  03-04
Zymeworks Is Maintained at Outperform by Leerink Partners
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
TIPRANKS  ·  03-03
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Zymeworks (ZYME) and Senseonics Holdings (SENS)
TIPRANKS  ·  03-03
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Zymeworks (ZYME) and Senseonics Holdings (SENS)
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
TIPRANKS  ·  03-03
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty
TIPRANKS  ·  03-03
Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty
Zymeworks Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-02
Zymeworks Inc reports results for the quarter ended December 31 - Earnings Summary
Zymeworks Publishes Corporate Presentation on Royalty-Driven Growth Strategy and Oncology Pipeline Progress
Reuters  ·  03-02
Zymeworks Publishes Corporate Presentation on Royalty-Driven Growth Strategy and Oncology Pipeline Progress
Zymeworks Q4 Net Loss Widens, Revenue Falls; Enters $250 Million Financing Agreement with Royalty Pharma
MT Newswires Live  ·  03-02
Zymeworks Q4 Net Loss Widens, Revenue Falls; Enters $250 Million Financing Agreement with Royalty Pharma
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
TIPRANKS  ·  03-02
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
Earnings Flash (ZYME) Zymeworks Posts Q4 Revenue $2.5M, vs. FactSet Est of $19.2M
MT Newswires Live  ·  03-02
Earnings Flash (ZYME) Zymeworks Posts Q4 Revenue $2.5M, vs. FactSet Est of $19.2M
Zymeworks reports Q4 EPS (55c) vs. (31c) last year
TIPRANKS  ·  03-02
Zymeworks reports Q4 EPS (55c) vs. (31c) last year
Earnings Flash (ZYME) Zymeworks Posts Q4 Net Loss $0.55 a Share, vs. FactSet Est of $0.46 Loss
MT Newswires Live  ·  03-02
Earnings Flash (ZYME) Zymeworks Posts Q4 Net Loss $0.55 a Share, vs. FactSet Est of $0.46 Loss
Canada's Zymeworks 2025 revenue rises 39%
Reuters  ·  03-02
Canada's Zymeworks 2025 revenue rises 39%
Zymeworks Q4 2025 EPS $(0.55) Misses $(0.42) Estimate, Sales $2.515M Miss $13.576M Estimate
Benzinga  ·  03-02
Zymeworks Q4 2025 EPS $(0.55) Misses $(0.42) Estimate, Sales $2.515M Miss $13.576M Estimate
Zymeworks and Royalty Pharma Enter Into $250 Million Royalty-Backed Note Financing
THOMSON REUTERS  ·  03-02
Zymeworks and Royalty Pharma Enter Into $250 Million Royalty-Backed Note Financing

Introduction

Company Name.
ZYMEWORKS INC (US)
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--